Researchers are turning to viruses that prey on bacteria as a potential answer to infections that no longer respond to antibiotics. The approach, known as phage therapy, uses bacteriophages, viruses that infect and kill specific harmful bacteria while leaving human cells alone. Interest in the method has grown as drug-resistant superbugs spread, but it remains experimental and is not yet part of routine clinical care.
An international team has now published the first coordinated guidelines for personalized phage therapy, in which treatment is matched to the particular bacteria causing an individual patient's infection. The team presented the document as a roadmap for using the therapy safely in hospitals and clinics, addressing how the viruses are selected and how patients should be monitored once treatment begins.
Early evidence is promising. In one study cited by the researchers, 77 percent of patients improved, and the targeted bacteria were eliminated in 61 percent of them. Those figures come from a single study, however, and the wider body of evidence is still thin. It remains unclear whether the same results would hold up across larger trials involving more patients and more varied infections.
For now, the guidelines are meant to give clinicians a shared framework rather than settle the open questions. Working out how phage therapy can be integrated safely into standard care is still ongoing, and the researchers acknowledge that larger studies will be needed before the treatment can be widely adopted.
Credit. Based on reporting for ScienceDaily. Is this your work? Write to us.
5
